Beijing Life Science Hub Aims to Accelerate Drug Innovation

Published: Oct. 1, 2025 11:59 a.m. GMT+8

00:00

00:00/00:00

Listen to this article 1x

Zhongguancun Life Science Park is fostering a full-chain ecosystem to shorten drug development cycles. Photo: VCG

A sprawling life sciences hub in Beijing is accelerating its drive to turn laboratory breakthroughs into marketable innovative drugs, central to China’s pursuit of global competitiveness in the pharmaceutical sector.

The Zhongguancun Life Science Park, located in the capital’s Changping district, is nurturing an ecosystem that integrates basic research, clinical development, manufacturing and healthcare services. An innovative treatment for hepatitis B and D developed by a company based at the park is already nearing conditional approval.

Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.

Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.

Disclaimer

This is an AI-generated English rendering of original reporting or commentary published by Caixin Media. In the event of any discrepancies, the Chinese version shall prevail.

Share this article

Open WeChat and scan the QR code

DIGEST HUB

Digest Hub

Back

Explore the story in 30 seconds

Zhongguancun Life Science Park in Beijing hosts over 1,000 pharma companies and integrates research, clinical development, and manufacturing to boost China’s pharmaceutical innovation.
A hepatitis B and D drug by Huahui Health Ltd. is expected to receive conditional approval by late 2025 or early 2026; the park fosters breakthroughs in cell/gene therapy, AI health tech, and neuroscience.
The park supports startups with nearly 60 service platforms, contributing to about 5% of China’s CGT clinical trials and 40% of Beijing’s AI medical device certificates.

AI generated, for reference only

Who’s Who

Huahui Health Ltd.: Huahui Health Ltd. is a pharmaceutical firm co-founded by Li Wenhui, a senior researcher at NIBS. Their flagship drug, Libeiweita, a monoclonal antibody for treating hepatitis B and D, is expected to receive conditional marketing approval on the Chinese mainland by late 2025 or early 2026. This drug, based on research from Li's team, has been granted "breakthrough therapy" designation in both China and the U.S.

AI generated, for reference only

GALLERY

: Gallery: Asia New Vision Forum Kicks Off in Singapore

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

Caixin Deep Dive: Former Securities Regulator Yi Huiman’s Corruption Probe

00:00

00:00/00:00

MOST POPULAR

1: Exclusive: Trump Signs Deal Keeping TikTok Online With New U.S.-Controlled Venture

2: In Depth: Starbucks, Burger King Overhaul China Strategies

3: China Launches 18-Day Arctic Shipping Route to Europe Amid Global Trade Turmoil

4: In Depth: Beijing Bets on New Policy Tool to Bolster Emerging Sector Investment

5: Shanghai Raises Margins on Gold, Silver Amid Fed-Driven Market Frenzy